Vascular Endothelial Growth Factor A (VEGFA) Antibody Pair
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
Vascular Endothelial Growth Factor A (VEGFA) Antibody Pair for use in Sandwich ELISA assay development.
Documents del producto
Product specifications
| Category | Antibody Pairs |
| Immunogen Target | Vascular Endothelial Growth Factor A (VEGFA) |
| Reactivity | Rat |
| Assay Data | Detection Antibody Biotinilated |
| Assay Type | Sandwich |
| Recommended Dilution | Dilute the Capture Antibody 125-fold with Coating Buffer. Dilute the Biotin-Conjugated Detection Antibody 200-fold with Detection Antibody Diluent. Optimal dilutions/concentrations should be determined by the end user. |
| Size 1 | 5 × 96 tests |
| Size 2 | 10 × 96 tests |
| Form | Standard: Lyophilized--Liquid (Capture Antibody and Detection Antibody) Reconstitute the standard with Standard Diluent. The volume, and therefore standard concentration, should be determined by the end user. |
| Tested Applications | ELISA |
| Buffer | The Capture and Detection Antibody both contain 0.1% sodium azide. |
| Availability | Please enquire. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | L-VEGF,MVCD1,VEGF,VPF,Vascular permeability factor |
| Background | Antibody Pair for VEGFA |
| Status | RUO |
| Note | This antibody pair contains ( 5 x 96 det): Detection: 50 µg Capture: 200 µg Standard: 2 µg This product is for research use only. |
Descripción
VEGFA is a key member of the vascular endothelial growth factor (VEGF) family and plays a crucial role in angiogenesis, vascular permeability, and endothelial cell proliferation VEGFA binds primarily to its receptors VEGFR-1 and VEGFR-2, triggering signaling pathways like PI3K/AKT and ERK/MAPK to promote blood vessel formation during embryonic development, wound healing, and tissue repair Dysregulated VEGFA expression is associated with pathological angiogenesis observed in cancer, diabetic retinopathy, and age-related macular degeneration (AMD) VEGFA also increases vascular permeability by altering endothelial junctions, contributing to fluid leakage in conditions such as inflammation and tumors Targeted therapies, such as bevacizumab and other anti-VEGF agents, inhibit VEGFA activity to suppress angiogenesis and tumor growth in various cancers and ocular diseases
Related Products
Goat VEGF-A (Vascular Endothelial cell Growth Factor A) ELISA Kit
Ver Producto
Guinea pig VEGF-A (Vascular Endothelial cell Growth Factor A) ELISA Kit
Ver Producto
VEGFA antibody
VEGFA, also named as VEGF or VPF, belongs to the PDGF/VEGF growth factor family. It is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1(MVCD1). VEGFA has 13 isoforms with MW 16kd to 45kd. Some isoforms has homodimer form, such as VEGFA189(38kd), VEFGA110(34kd). VEGFA is a 34kd to 42kd, dimeric, disulfide-bound glycoprotein. VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 183, 189, or 206 amino acids(PMID:15602010).
Ver Producto